|
Chile Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Chile Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Chile .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Chilean pharmaceutical and healthcare industry.
Competitive intelligence, Chilean pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Chilean market.
The Chile Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Chile Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Chilean pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Chile to test other views – a key input for successful budgeting and strategic business planning in the Chilean pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Chilean Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Chile .
- Exploit The Latest Competitive Chilean Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Chile .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Chile Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Chile Pharmaceuticals And Healthcare Industry SWOT |
| Chile Political SWOT |
| Chile Economic SWOT |
| Chile Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Americas Pharmaceutical Business Environment Ratings for Q209 |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Chile – Market Summary |
| Regulatory Regime |
| Recent Regulatory Developments |
| Intellectual Property |
| IP Deficiencies |
| Recent IP Developments |
| Trade Agreements |
| Pricing Regime |
| Reimbursement Regime |
Chapter - Industry Developments |
| Epidemiology |
| DALYs Lost To All Diseases And Injuries Per 100,00 Population In Select South American Countries |
| Healthcare Sector |
| Healthcare Insurance |
| Pharmaceutical Sector |
| Table: Latin American Regulations On Bioequivalence And GMP |
| Domestic Industry |
| Foreign Industry |
| Recent Pharmaceutical Industry Developments |
| OTC Medicines |
| Pharmaceutical Retail Sector |
| Clinical Trials |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Chile - Drug Market Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Industry |
| Table: Chile - Health Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Macroeconomic |
| Table: Chile - Economic Activity |
| Prescription Market Forecast |
| Table: Chile - Prescription Market Indicators, Historical Data and Forecasts (CLPmn unless otherwise stated) |
| Patented Market Forecast |
| Generics Market Forecast |
| OTC Market Forecast |
| Table: Chile - OTC Market Indicators, Historical Data and Forecasts (CLPmn unless otherwise stated) |
| Pharmaceutical Trade Forecast |
| Table: Chile - Pharmaceutical Trade Indicators, Historical Data and Forecasts (US$mn) |
| Medical Devices Forecasts |
| Table: Chile - Medical Device Indicators, Historical Data And Forecasts (US$mn unless otherwise stated) |
| Other Healthcare Data |
| Table: Chile - Other Healthcare Indicators, Historical Data and Forecasts |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Company Monitor |
| Leading Multinationals |
| Pfizer |
| Novartis |
| GlaxoSmithKline (GSK) |
| Sanofi-Aventis |
| Merck & Co |
| Indigenous Companies |
| Laboratorios Chile (LabChile) |
| Laboratorios Andrómaco |
| Laboratorios Maver |
Chapter - Country Snapshot: Chile Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Chile Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chile remains seventh overall in BMI‘s Q209 Business Environment Rankings for the 10 markets of the Americas. In the next five years, we expect that the country’s pharmaceutical market will experience a compound annual growth rate (CAGR) of 7.38% in US dollar terms (or 4.81% in local currency terms, as the peso appreciates against the US dollar), reaching CLP802.81bn (US$1.73bn) at consumer prices in 2013. The main drivers of this trend will be economic growth (despite an expected blip of a slowdown in 2009), higher government spending, expansion of universal insurance and epidemiological concerns, as well as the expected introduction of tougher bioequivalence standards.
On the negative side, a key drawback to investing in the market comes from the government’s minimal provision of or reimbursement for medicines, despite the expansion of government spending in recent years, particularly under the flagship Universal Access and Explicit Guarantees (AUGE) healthcare plan. Similarly, future value growth will depend on the speed at which Chile aligns its intellectual property (IP) regulations with its international obligations. In this field, much depends on the government’s success in balancing its healthcare reforms and the need to restrain cost growth with the desire to placate its international trading partners. Additionally, private sector retail drug prices remain low, primarily owing to intense retail sector competition, although formal pricing restrictions are relatively limited.
In the meantime, individuals in Latin America continue to succumb to generally preventable diseases such as gastric and cervical cancers. For example, BMI's Burden of Disease Database (BoDD) reveals that, in 2008, Chile lost 147,495 disability-adjusted life years (DALYs) to cancer. The growing cancer burden has recently led to launch of a new Office of Latin American Cancer Program Development (OLACPD) by the National Cancer Institute (NIC), the National Institutes of Health (NIH). The programme, which will initially focus on Mexico, Brazil, Chile, Argentina and Uruguay, aims to gain a better understanding of the status of the cancer burden, research and treatment infrastructures in those countries.
On an economic front, a stable political outlook and sound economic fundamentals position Chile for steady economic progress, and underpin our view that Chile's economy will head towards developed state status by 2018. While obstacles such as high reliance on copper exports and oil imports continue to limit the scope for economic progress, we see encouraging developments in both areas over the next ten years. However, an economic recovery among Latin American economies will be vital for Chile, as regional trade will provide an important platform for growth in the next decade.
|
Chile Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |